CA2969334A1 - Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism - Google Patents
Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism Download PDFInfo
- Publication number
- CA2969334A1 CA2969334A1 CA2969334A CA2969334A CA2969334A1 CA 2969334 A1 CA2969334 A1 CA 2969334A1 CA 2969334 A CA2969334 A CA 2969334A CA 2969334 A CA2969334 A CA 2969334A CA 2969334 A1 CA2969334 A1 CA 2969334A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- secondary hyperparathyroidism
- administered
- therapeutically effective
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 title claims abstract description 89
- 230000002092 calcimimetic effect Effects 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 45
- 208000024891 symptom Diseases 0.000 claims abstract description 43
- 210000002966 serum Anatomy 0.000 claims description 52
- 208000020832 chronic kidney disease Diseases 0.000 claims description 35
- 238000011282 treatment Methods 0.000 claims description 29
- 239000002552 dosage form Substances 0.000 claims description 28
- 238000002347 injection Methods 0.000 claims description 23
- 239000007924 injection Substances 0.000 claims description 23
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 21
- 230000000148 hypercalcaemia Effects 0.000 claims description 21
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 21
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 16
- 229910052698 phosphorus Inorganic materials 0.000 claims description 14
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 13
- 239000011574 phosphorus Substances 0.000 claims description 13
- 229940109239 creatinine Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 238000001631 haemodialysis Methods 0.000 claims description 5
- 230000000322 hemodialysis Effects 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 3
- UHMPCVGLSKFXHR-NFZXMVPNSA-N (1r,3r)-5-[(2e)-2-[(3as,7ar)-1-[(2s)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-2-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CCC([C@]2(CCC1)C)[C@H](CCCC(C)(C)O)C)=C\C=C1C[C@@H](O)C(=C)[C@H](O)C1 UHMPCVGLSKFXHR-NFZXMVPNSA-N 0.000 claims 4
- 239000011575 calcium Substances 0.000 description 50
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 49
- 229910052791 calcium Inorganic materials 0.000 description 48
- 239000003814 drug Substances 0.000 description 42
- 102000003982 Parathyroid hormone Human genes 0.000 description 41
- 108090000445 Parathyroid hormone Proteins 0.000 description 41
- 229940079593 drug Drugs 0.000 description 41
- 239000000199 parathyroid hormone Substances 0.000 description 41
- 229960001319 parathyroid hormone Drugs 0.000 description 41
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 28
- 229960005084 calcitriol Drugs 0.000 description 24
- 235000020964 calcitriol Nutrition 0.000 description 24
- 239000011612 calcitriol Substances 0.000 description 24
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 23
- 239000000203 mixture Substances 0.000 description 23
- 229930003316 Vitamin D Natural products 0.000 description 22
- 235000019166 vitamin D Nutrition 0.000 description 22
- 239000011710 vitamin D Substances 0.000 description 22
- 229940046008 vitamin d Drugs 0.000 description 22
- 239000003826 tablet Substances 0.000 description 21
- 229940090044 injection Drugs 0.000 description 19
- 208000017169 kidney disease Diseases 0.000 description 18
- 210000002990 parathyroid gland Anatomy 0.000 description 18
- 150000003710 vitamin D derivatives Chemical class 0.000 description 18
- 239000007788 liquid Substances 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 239000002775 capsule Substances 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 238000013265 extended release Methods 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 239000008186 active pharmaceutical agent Substances 0.000 description 11
- 210000000988 bone and bone Anatomy 0.000 description 11
- 238000000502 dialysis Methods 0.000 description 11
- 239000005414 inactive ingredient Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 206010053260 Secondary hyperthyroidism Diseases 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 208000001647 Renal Insufficiency Diseases 0.000 description 9
- 239000000443 aerosol Substances 0.000 description 9
- 229960003315 cinacalcet Drugs 0.000 description 9
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 238000012377 drug delivery Methods 0.000 description 9
- 201000006370 kidney failure Diseases 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- -1 vitamin D compounds Chemical class 0.000 description 9
- 108010010803 Gelatin Proteins 0.000 description 8
- DTXXSJZBSTYZKE-ZDQKKZTESA-N Maxacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](OCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C DTXXSJZBSTYZKE-ZDQKKZTESA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 239000008273 gelatin Substances 0.000 description 8
- 229920000159 gelatin Polymers 0.000 description 8
- 235000019322 gelatine Nutrition 0.000 description 8
- 235000011852 gelatine desserts Nutrition 0.000 description 8
- 229950006319 maxacalcitol Drugs 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 239000007909 solid dosage form Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 6
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 6
- 208000013038 Hypocalcemia Diseases 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000001747 exhibiting effect Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000000705 hypocalcaemia Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000232 Lipid Bilayer Substances 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 229940088679 drug related substance Drugs 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 239000006186 oral dosage form Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000006208 topical dosage form Substances 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940126534 drug product Drugs 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 239000008297 liquid dosage form Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000008299 semisolid dosage form Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 3
- 206010051714 Calciphylaxis Diseases 0.000 description 3
- 208000000913 Kidney Calculi Diseases 0.000 description 3
- 206010029148 Nephrolithiasis Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000003416 augmentation Effects 0.000 description 3
- 230000003190 augmentative effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000009310 vitamin D receptors Human genes 0.000 description 3
- 108050000156 vitamin D receptors Proteins 0.000 description 3
- BPKAHTKRCLCHEA-FOPGHSPUSA-N 19-Nor-1-α,25-dihydroxyvitamin D2 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](C=C[C@H](C)C(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-FOPGHSPUSA-N 0.000 description 2
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 description 2
- JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 description 2
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010070918 Bone deformity Diseases 0.000 description 2
- 206010006002 Bone pain Diseases 0.000 description 2
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 2
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 2
- 206010020669 Hypermagnesaemia Diseases 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010025476 Malabsorption Diseases 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 208000006670 Multiple fractures Diseases 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 206010033649 Pancreatitis chronic Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 2
- 201000006035 X-linked dominant hypophosphatemic rickets Diseases 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000007681 bariatric surgery Methods 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000000125 calcaemic effect Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 229960002061 ergocalciferol Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 208000011111 hypophosphatemic rickets Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000009136 lithium therapy Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000000849 parathyroid Effects 0.000 description 2
- 229960000987 paricalcitol Drugs 0.000 description 2
- BPKAHTKRCLCHEA-UBFJEZKGSA-N paricalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 2
- 201000006409 renal osteodystrophy Diseases 0.000 description 2
- 238000012959 renal replacement therapy Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000001962 taste-modifying agent Substances 0.000 description 2
- 239000006211 transdermal dosage form Substances 0.000 description 2
- 208000032349 type 2B vitamin D-dependent rickets Diseases 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 239000011653 vitamin D2 Substances 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010060737 Congenital nephrotic syndrome Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 206010018374 Glomerulonephritis minimal lesion Diseases 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023424 Kidney infection Diseases 0.000 description 1
- 208000004883 Lipoid Nephrosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010065673 Nephritic syndrome Diseases 0.000 description 1
- 201000005118 Nephrogenic diabetes insipidus Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010065427 Reflux nephropathy Diseases 0.000 description 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
- 206010038378 Renal artery stenosis Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010063544 Renal embolism Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 206010038491 Renal papillary necrosis Diseases 0.000 description 1
- 206010038548 Renal vein thrombosis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 201000004954 familial nephrotic syndrome Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 201000000173 nephrocalcinosis Diseases 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940105640 paricalcitol injection Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000003173 phosphatemic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000010384 renal tubular acidosis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012066 statistical methodology Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940052212 zemplar Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098112P | 2014-12-30 | 2014-12-30 | |
| US62/098,112 | 2014-12-30 | ||
| US14/710,746 | 2015-05-13 | ||
| US14/710,746 US9539264B2 (en) | 2014-12-30 | 2015-05-13 | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
| PCT/US2015/065175 WO2016109156A1 (en) | 2014-12-30 | 2015-12-11 | Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2969334A1 true CA2969334A1 (en) | 2016-07-07 |
Family
ID=56162990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2969334A Abandoned CA2969334A1 (en) | 2014-12-30 | 2015-12-11 | Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9539264B2 (enExample) |
| EP (1) | EP3240549A4 (enExample) |
| JP (1) | JP2018500375A (enExample) |
| AU (1) | AU2015374468A1 (enExample) |
| CA (1) | CA2969334A1 (enExample) |
| WO (1) | WO2016109156A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9539264B2 (en) * | 2014-12-30 | 2017-01-10 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
| US10105375B2 (en) | 2016-08-30 | 2018-10-23 | Wisconsin Alumni Research Foundation | Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040043971A1 (en) | 1995-04-03 | 2004-03-04 | Bone Care International, Inc. | Method of treating and preventing hyperparathyroidism with active vitamin D analogs |
| US5843928A (en) | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
| US6306844B1 (en) | 1997-03-17 | 2001-10-23 | Wisconsin Alumni Research Foundation | Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength |
| US6136799A (en) | 1998-04-08 | 2000-10-24 | Abbott Laboratories | Cosolvent formulations |
| US6673782B2 (en) | 1999-04-29 | 2004-01-06 | Wisconsin Alumni Research Foundation | Treatment of systemic lupus erythematosis |
| CA2404335C (en) | 2000-03-27 | 2009-01-06 | Wisconsin Alumni Research Foundation | Vitamin d compounds used to stabilize kidney transplants |
| MXPA03000406A (es) | 2000-07-14 | 2003-06-06 | Wisconsin Alumni Res Found | Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos. |
| US20080249068A1 (en) | 2002-09-05 | 2008-10-09 | Deluca Hector F | Method of Extending the Dose Range of Vitamin D Compounds |
| US20050124591A1 (en) | 2003-07-29 | 2005-06-09 | Jin Tian | Use of vitamin Ds to treat kidney disease |
| US20060171983A1 (en) | 2003-07-30 | 2006-08-03 | Jin Tian | Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease |
| US7704980B2 (en) | 2003-10-08 | 2010-04-27 | Wisconsin Alumni Research Foundation | Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds |
| US7214671B2 (en) | 2004-02-19 | 2007-05-08 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases |
| EP1853274B1 (en) | 2005-02-11 | 2013-01-23 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor- (20s-24s) - 1alpha, 25-dihydroxyvitamine-d2 |
| US20060276534A1 (en) | 2005-03-17 | 2006-12-07 | Amgen Inc. | Methods of decreasing calcification |
| EP2001832A1 (en) * | 2006-03-23 | 2008-12-17 | Amgen Inc. | Methods and compositions for making and using polymorphs of cinacalcet |
| DK3225243T3 (da) * | 2007-04-25 | 2025-09-29 | Opko Renal Llc | Metode til sikker og effektiv behandling og forebyggelse af sekundær hyperparatyreoidisme ved kronisk nyresygdom |
| CA2764577C (en) | 2009-08-03 | 2017-12-19 | Wisconsin Alumni Research Foundation | Method of preventing renal disease and treating symptoms thereof |
| CA2794006C (en) | 2010-03-23 | 2017-11-28 | Wisconsin Alumni Research Foundation | (20s)-2-methylene-19-nor-22-dimethyl-1.alpha.,25-dihydroxyvitamin d3 and (20r)-2-methylene-19-nor-22-dimethyl-1.alpha.,25-hydroxyvitamin d3 |
| AU2012335009B2 (en) * | 2011-11-10 | 2017-08-31 | Kai Pharmaceuticals, Inc. | Calcimimetics and methods for their use |
| US20130295083A1 (en) | 2012-05-02 | 2013-11-07 | Wisconsin Alumni Research Foundation | 2a-Methyl-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2AMD) or 2 methylene-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2MD) Support Survival and Function of Transplanted Islet Cells In Type 1 Diabetes |
| MY172886A (en) | 2012-06-29 | 2019-12-13 | Wisconsin Alumni Res Found | Use of 2-methylene-19-nor-(20s)-1?25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism |
| US9539264B2 (en) * | 2014-12-30 | 2017-01-10 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
-
2015
- 2015-05-13 US US14/710,746 patent/US9539264B2/en not_active Expired - Fee Related
- 2015-12-11 JP JP2017534946A patent/JP2018500375A/ja active Pending
- 2015-12-11 WO PCT/US2015/065175 patent/WO2016109156A1/en not_active Ceased
- 2015-12-11 CA CA2969334A patent/CA2969334A1/en not_active Abandoned
- 2015-12-11 EP EP15875945.6A patent/EP3240549A4/en not_active Withdrawn
- 2015-12-11 AU AU2015374468A patent/AU2015374468A1/en not_active Abandoned
-
2016
- 2016-10-31 US US15/338,924 patent/US9814736B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US9814736B2 (en) | 2017-11-14 |
| JP2018500375A (ja) | 2018-01-11 |
| WO2016109156A1 (en) | 2016-07-07 |
| US20170042913A1 (en) | 2017-02-16 |
| AU2015374468A1 (en) | 2017-06-22 |
| US20160184328A1 (en) | 2016-06-30 |
| EP3240549A4 (en) | 2018-08-29 |
| US9539264B2 (en) | 2017-01-10 |
| EP3240549A1 (en) | 2017-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10046000B2 (en) | Use of 2-methylene-19-nor-(20S)-1α,25-Dihydroxyvitamin D3 to treat and prevent secondary hyperparathyroidism in a subject having renal failure | |
| JP6375353B2 (ja) | ２５−ヒドロキシビタミンｄ３を含む経口剤形、及び、その経口剤形を週１回ヒトに投与することを含む方法 | |
| ES2437921T3 (es) | Método para prevenir la diabetes tipo 1 | |
| EP2461815B1 (en) | Method of preventing renal disease and treating symptoms thereof | |
| US9814736B2 (en) | Use of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism | |
| JP7507772B2 (ja) | 筋痙攣の予防及び治療のためのケイ素及びマグネシウムの組合せ物 | |
| US10105375B2 (en) | Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism | |
| US10369161B2 (en) | Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220304 |